Role of the progesterone receptor for paclitaxel resistance in primary breast cancer

Détails

Ressource 1Télécharger: 17211474.pdf (132.27 [Ko])
Etat: Serval
Version: Final published version
ID Serval
serval:BIB_7C8C8C23B2EE
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Titre
Role of the progesterone receptor for paclitaxel resistance in primary breast cancer
Périodique
British Journal of Cancer
Auteur(s)
Schmidt M., Bremer E., Hasenclever D., Victor A., Gehrmann M., Steiner E., Schiffer I. B., Gebhardt S., Lehr H. A., Mahlke M., Hermes M., Mustea A., Tanner B., Koelbl H., Pilch H., Hengstler J. G.
ISSN
0007-0920 (Print)
Statut éditorial
Publié
Date de publication
2007
Volume
96
Numéro
2
Pages
241-247
Langue
anglais
Notes
PT - Journal Article PT - Research Support, Non-U.S. Gov't
Résumé
Paclitaxel plays an important role in the treatment of primary breast cancer. However, a substantial proportion of patients treated with paclitaxel does not appear to derive any benefit from this therapy. We performed a prospective study using tumour cells isolated from 50 primary breast carcinomas. Sensitivity of primary tumour cells to paclitaxel was determined in a clinically relevant range of concentrations (0.85-27.2 microg ml(-1) paclitaxel) using an ATP assay. Chemosensitivity data were used to study a possible association with immunohistochemically determined oestrogen and progesterone receptor (ER and PR) status, as well as histopathological parameters. Progesterone receptor (PR) mRNA expression was also determined by quantitative RT-PCR. We observed a clear association of the PR status with chemosensitivity to paclitaxel. Higher levels of immunohistochemically detected PR expression correlated with decreased chemosensitivity (P=0.008). Similarly, high levels of PR mRNA expression were associated with decreased paclitaxel chemosensitivity (P=0.007). Cells from carcinomas with T-stages 3 and 4 were less sensitive compared to stages 1 and 2 (P=0.013). Multiple regression analysis identified PR receptor status and T-stage as independent predictors of paclitaxel chemosensitivity, whereas the ER, N-stage, grading and age were not influential. In conclusion, in vitro sensitivity to paclitaxel was higher for PR-negative compared with PR-positive breast carcinoma cells. Thus, PR status should be considered as a possible factor of influence when designing new trials and chemotherapy protocols
Mots-clé
Antineoplastic Agents,Phytogenic/therapeutic use/Base Sequence/Breast Neoplasms/Pathology/DNA Probes/Dose-Response Relationship,Drug/Drug Resistance,Neoplasm/Humans/Immunohistochemistry/Paclitaxel/RNA,Messenger/genetics/Receptors,Progesterone/physiology
Pubmed
Web of science
Création de la notice
29/01/2008 19:36
Dernière modification de la notice
20/10/2018 7:08
Données d'usage